FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2266565546> ?p ?o ?g. }

• W2266565546 endingPage "405" @default.
• W2266565546 startingPage "405" @default.
• W2266565546 abstract "PURPOSE: To determine the maximum-tolerated dose of gemcitabine when combined with a fixed dose of vinorelbine in the treatment of non–small-cell lung cancer (NSCLC) and to evaluate in a phase II trial the activity of this combination. PATIENTS AND METHODS: Sixty-eight patients with stage IIIB/IV NSCLC were treated with vinorelbine at fixed dose of 30 mg/m 2 intravenously and gemcitabine at increasing dose levels from 800 to 1,500 mg/m 2 intravenously on days 1 and 8 every 3 weeks. RESULTS: In phase I, dose-limiting toxicity occurred at the dosage of 1,500 mg/m 2 gemcitabine, with three of five patients developing grade 4 thrombocytopenia. In phase II, with gemcitabine at 1,200 mg/m 2 , 19 (36%) of 52 assessable patients responded. Objective response was observed in 11 (39%) of 28 patients with stage IIIB disease and in eight (33%) of 24 patients with stage IV. The median time to progression was 29 weeks (range, 2 to 41 weeks; 35 weeks and 16 weeks for stages IIIB and IV, respectively), and median survival was 54 weeks (range, 2 to 84+ weeks; 63 weeks and 42 weeks for stages IIIB and IV, respectively). One-year survival was 64% for patients with stage IIIB disease and 29% for those with stage IV. Clinical benefit response was observed in 29 (59%) of 49 assessable patients. Grade 4 leukopenia and thrombocytopenia were uncommon (6% and 8% of cases, respectively); however, grade 3/4 leukothrombocytopenia occurred more frequently in patients aged more than 70 years (52% and 24%, respectively). CONCLUSION: The combination of vinorelbine and gemcitabine is effective and tolerable in the treatment of NSCLC, thus deserving randomized trials with cisplatin combination regimens." @default.
• W2266565546 created "2016-06-24" @default.
• W2266565546 creator A5006434076 @default.
• W2266565546 creator A5007631430 @default.
• W2266565546 creator A5008166009 @default.
• W2266565546 creator A5015849958 @default.
• W2266565546 creator A5028903159 @default.
• W2266565546 creator A5037659860 @default.
• W2266565546 creator A5043924324 @default.
• W2266565546 creator A5051722602 @default.
• W2266565546 creator A5063347918 @default.
• W2266565546 creator A5070951382 @default.
• W2266565546 creator A5079690778 @default.
• W2266565546 creator A5090055323 @default.
• W2266565546 date "2000-01-01" @default.
• W2266565546 modified "2023-10-11" @default.
• W2266565546 title "Phase I/II Study of Gemcitabine Plus Vinorelbine as First-Line Chemotherapy of Non–Small-Cell Lung Cancer" @default.
• W2266565546 cites W1788009048 @default.
• W2266565546 cites W1857358013 @default.
• W2266565546 cites W1858072261 @default.
• W2266565546 cites W1917502393 @default.
• W2266565546 cites W1938837918 @default.
• W2266565546 cites W1964842293 @default.
• W2266565546 cites W1965352960 @default.
• W2266565546 cites W1967832506 @default.
• W2266565546 cites W1989339760 @default.
• W2266565546 cites W2001996041 @default.
• W2266565546 cites W2003562529 @default.
• W2266565546 cites W2016263166 @default.
• W2266565546 cites W2026848003 @default.
• W2266565546 cites W2050312345 @default.
• W2266565546 cites W2086993950 @default.
• W2266565546 cites W2100055125 @default.
• W2266565546 cites W2128746268 @default.
• W2266565546 cites W2129793485 @default.
• W2266565546 cites W2256453366 @default.
• W2266565546 cites W2264414928 @default.
• W2266565546 cites W4239714259 @default.
• W2266565546 doi "https://doi.org/10.1200/jco.2000.18.2.405" @default.
• W2266565546 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10637256" @default.
• W2266565546 hasPublicationYear "2000" @default.
• W2266565546 type Work @default.
• W2266565546 sameAs 2266565546 @default.
• W2266565546 citedByCount "81" @default.
• W2266565546 countsByYear W22665655462013 @default.
• W2266565546 countsByYear W22665655462014 @default.
• W2266565546 countsByYear W22665655462015 @default.
• W2266565546 crossrefType "journal-article" @default.
• W2266565546 hasAuthorship W2266565546A5006434076 @default.
• W2266565546 hasAuthorship W2266565546A5007631430 @default.
• W2266565546 hasAuthorship W2266565546A5008166009 @default.
• W2266565546 hasAuthorship W2266565546A5015849958 @default.
• W2266565546 hasAuthorship W2266565546A5028903159 @default.
• W2266565546 hasAuthorship W2266565546A5037659860 @default.
• W2266565546 hasAuthorship W2266565546A5043924324 @default.
• W2266565546 hasAuthorship W2266565546A5051722602 @default.
• W2266565546 hasAuthorship W2266565546A5063347918 @default.
• W2266565546 hasAuthorship W2266565546A5070951382 @default.
• W2266565546 hasAuthorship W2266565546A5079690778 @default.
• W2266565546 hasAuthorship W2266565546A5090055323 @default.
• W2266565546 hasConcept C126322002 @default.
• W2266565546 hasConcept C141071460 @default.
• W2266565546 hasConcept C2776256026 @default.
• W2266565546 hasConcept C2776694085 @default.
• W2266565546 hasConcept C2778239845 @default.
• W2266565546 hasConcept C2778397455 @default.
• W2266565546 hasConcept C2780258809 @default.
• W2266565546 hasConcept C2780350996 @default.
• W2266565546 hasConcept C2780873365 @default.
• W2266565546 hasConcept C29730261 @default.
• W2266565546 hasConcept C31760486 @default.
• W2266565546 hasConcept C71924100 @default.
• W2266565546 hasConcept C90924648 @default.
• W2266565546 hasConceptScore W2266565546C126322002 @default.
• W2266565546 hasConceptScore W2266565546C141071460 @default.
• W2266565546 hasConceptScore W2266565546C2776256026 @default.
• W2266565546 hasConceptScore W2266565546C2776694085 @default.
• W2266565546 hasConceptScore W2266565546C2778239845 @default.
• W2266565546 hasConceptScore W2266565546C2778397455 @default.
• W2266565546 hasConceptScore W2266565546C2780258809 @default.
• W2266565546 hasConceptScore W2266565546C2780350996 @default.
• W2266565546 hasConceptScore W2266565546C2780873365 @default.
• W2266565546 hasConceptScore W2266565546C29730261 @default.
• W2266565546 hasConceptScore W2266565546C31760486 @default.
• W2266565546 hasConceptScore W2266565546C71924100 @default.
• W2266565546 hasConceptScore W2266565546C90924648 @default.
• W2266565546 hasIssue "2" @default.
• W2266565546 hasLocation W22665655461 @default.
• W2266565546 hasLocation W22665655462 @default.
• W2266565546 hasOpenAccess W2266565546 @default.
• W2266565546 hasPrimaryLocation W22665655461 @default.
• W2266565546 hasRelatedWork W1911331 @default.
• W2266565546 hasRelatedWork W1980117151 @default.
• W2266565546 hasRelatedWork W2077610667 @default.
• W2266565546 hasRelatedWork W2086403032 @default.
• W2266565546 hasRelatedWork W2098840563 @default.
• W2266565546 hasRelatedWork W2391481332 @default.
• W2266565546 hasRelatedWork W2797744674 @default.

• next